Evidence map›Paper›PMID 24135224›Full record

ArticleMultidisciplinary respiratory medicine2013

Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease.

Nuri Tutar, Gokhan Metan, Ayşe Nedret Koç, Insu Yilmaz, Ilkay Bozkurt, Zuhal Ozer Simsek, Hakan Buyukoglan, Asiye Kanbay, Fatma Sema Oymak, Inci Gulmez and 1 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Multidisciplinary respiratory medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02234739 (Efficacy and Safety of Voriconazole for Treatment of Invasive Pulmonary Aspergillosis Secondary to COPD), which is not on this map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02234739 phase4unknown statusnot on this mapstarted 2014, after this paper: background citation

Efficacy and Safety of Voriconazole for Treatment of Invasive Pulmonary Aspergillosis Secondary to COPD: a Multi-center Prospective,Open Cohort Study (VIA-COPD)

TypeinterventionalSponsorRed Cross Hospital, Hangzhou, ChinaRan2014 to 2016Enrolled40ConditionsInvasive Pulmonary Aspergillosis, COPDArmsVoriconazole
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Observational
  4. Review
  5. Role of COPD in a case of fatalBMJ case reports · 2023
    Article
  6. Article
  7. Polymorphisms within theInfection and immunity · 2020
    Article
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Nuri TutarDepartment of Pulmonary Medicine, Erciyes University Faculty of Medicine, Kayseri 38039, Turkey.
Gokhan MetanDepartment of Infectious Diseases and Clinical Microbiology, Erciyes University Faculty of Medicine, Kayseri, Turkey.
Ayşe Nedret KoçDepartment of Microbiology, Kayseri, Turkey.
Insu YilmazDepartment of Pulmonary Medicine, Erciyes University Faculty of Medicine, Kayseri 38039, Turkey.
Ilkay BozkurtDepartment of Infectious Diseases and Clinical Microbiology, Erciyes University Faculty of Medicine, Kayseri, Turkey.
Zuhal Ozer SimsekDepartment of Pulmonary Medicine, Erciyes University Faculty of Medicine, Kayseri 38039, Turkey.
Hakan BuyukoglanDepartment of Pulmonary Medicine, Erciyes University Faculty of Medicine, Kayseri 38039, Turkey.
Asiye KanbayDepartment of Pulmonary Medicine, Erciyes University Faculty of Medicine, Kayseri 38039, Turkey.
Fatma Sema OymakDepartment of Pulmonary Medicine, Erciyes University Faculty of Medicine, Kayseri 38039, Turkey.
Inci GulmezDepartment of Pulmonary Medicine, Erciyes University Faculty of Medicine, Kayseri 38039, Turkey.
Ramazan DemirDepartment of Pulmonary Medicine, Erciyes University Faculty of Medicine, Kayseri 38039, Turkey.
Erciyes University · TRKayseri Eğitim ve Araştırma Hastanesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInvasive pulmonary aspergillosis (IPA) is an infection often occurring in neutropenic patients and has high mortality rates. In recent years, it has been reported that the incidence of IPA has also increased in patients with chronic obstructive pulmonary disease (COPD). The purpose of this study is to investigate the clinical and demographic characteristics and treatment responses of IPA in patients with COPD.

methodsSeventy-one patients with a positive culture of Aspergillus from lower respiratory tract samples were examined retrospectively. Eleven (15.4%) of these patients, affected with grade 3 or 4 COPD, had IPA.

resultsAspergillus hyphae were detected in lung biopsy in three (27.3%) out of 11 patients and defined as proven IPA; a pathological sample was not taken in the other eight (72.7%) patients, and these were defined as probable IPA. Aspergillus isolates were identified as six cases of Aspergillusfumigatus and three of Aspergillusniger in nine patients, while two isolates were not identified at species level. While five patients required intensive care unit admission, four of them received mechanical ventilation. The most common finding on chest X-ray and computed tomography (CT) (respectively 63.6%, 72.7%) was infiltration. Amphotericin B was the initial drug of choice in all patients and five patients were discharged with oral voriconazole after amphotericin B therapy. Six patients (54.5%) died before treatment was completed.

conclusionsIPA should be taken into account in the differential diagnosis particularly in patients with severe and very severe COPD presenting with dyspnea exacerbation, poor clinical status, and a new pulmonary infiltrate under treatment with broad-spectrum antibiotics and steroids.

Indexed as

AspergillosisChronic obstructive pulmonary diseaseCOPDInvasive pulmonary aspergillosis

Identifiers

PMID24135224
PMCPMC3765339
OpenAlexW2142854233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.